Argosy Research Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Argosy Research heeft een totaal eigen vermogen van NT$4.5B en een totale schuld van NT$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk NT$5.6B en NT$1.0B. De EBIT Argosy Research is NT$1.0B waardoor de rentedekking -17.1 is. Het heeft contanten en kortetermijnbeleggingen van NT$1.3B.

Belangrijke informatie

Verhouding schuld/eigen vermogen

NT$0

Schuld

Rente dekkingsratio	-17.1x
Contant	NT$1.34b
Aandelen	NT$4.50b
Totaal verplichtingen	NT$1.05b
Totaal activa	NT$5.55b

Recente financiële gezondheidsupdates

Is Argosy Research (GTSM:3217) Using Too Much Debt?

Feb 28

Recent updates

Are Strong Financial Prospects The Force That Is Driving The Momentum In Argosy Research Inc.'s GTSM:3217) Stock?

Dec 24

The 24% Return On Capital At Argosy Research (GTSM:3217) Got Our Attention

Dec 06

Argosy Research (GTSM:3217) Has Rewarded Shareholders With An Exceptional 999% Total Return On Their Investment

Nov 18

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$3.2B ) 3217 } overtreffen de korte termijn passiva ( NT$975.3M ).

Langlopende schulden: De kortetermijnactiva 3217 ( NT$3.2B ) overtreffen de langetermijnschulden ( NT$73.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 3217 is schuldenvrij.

Schuld verminderen: 3217 heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 2.6% was.

Schuldendekking: 3217 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: 3217 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Argosy Research Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Argosy Research (GTSM:3217) Using Too Much Debt?

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Argosy Research Inc. Announces New Nomination Committee

Argosy Research Inc. to Report Q3, 2024 Results on Nov 01, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations

Now 21% undervalued after recent price drop

Argosy Research Inc. to Report Q2, 2024 Results on Jul 24, 2024

Dividend of NT$6.40 announced

Argosy Research Inc. Approves Cash Dividends, Payable on July 31, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Argosy Research Inc. to Report Q1, 2024 Results on Apr 25, 2024

Price target increased by 14% to NT$200

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 23% undervalued

Argosy Research Inc., Annual General Meeting, Jun 12, 2024

Argosy Research Inc. Announces Resignation of Lu,Cheng-Xi as Chief Internal Auditor, Effective from February 29, 2024

Now 20% undervalued

Investor sentiment improves as stock rises 28%

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Upcoming dividend of NT$5.35 per share at 4.0% yield

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Now 20% undervalued

Now 23% undervalued

Consensus EPS estimates fall by 11%

Price target decreased to NT$81.00

Investor sentiment improved over the past week

Price target decreased to NT$81.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Upcoming dividend of NT$5.60 per share

Consensus revenue estimates fall by 15%

Price target decreased to NT$116

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target increased to NT$160

Investor sentiment improved over the past week

Price target increased to NT$141

Investor sentiment improved over the past week

Price target increased to NT$130

Third quarter 2021 earnings released: EPS NT$2.35 (vs NT$1.95 in 3Q 2020)

Price target decreased to NT$120

Second quarter 2021 earnings released: EPS NT$1.47 (vs NT$1.96 in 2Q 2020)

Upcoming dividend of NT$5.60 per share

Price target decreased to NT$144

Investor sentiment deteriorated over the past week

A Look At The Intrinsic Value Of Argosy Research Inc. (GTSM:3217)

Full year 2020 earnings released: EPS NT$7.20 (vs NT$5.34 in FY 2019)

Will Argosy Research (GTSM:3217) Become A Multi-Bagger?

Is Argosy Research (GTSM:3217) Using Too Much Debt?

New 90-day high: NT$134

How Does Argosy Research Inc. (GTSM:3217) Fare As A Dividend Stock?

New 90-day high: NT$121

Calculating The Fair Value Of Argosy Research Inc. (GTSM:3217)

Is There More To The Story Than Argosy Research's (GTSM:3217) Earnings Growth?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Argosy Research Inc.'s GTSM:3217) Stock?

The 24% Return On Capital At Argosy Research (GTSM:3217) Got Our Attention

Argosy Research (GTSM:3217) Has Rewarded Shareholders With An Exceptional 999% Total Return On Their Investment

Third quarter 2020 earnings released: EPS NT$1.95

New 90-day low: NT$105

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven